STOCK TITAN

Leveljump Health (JMPHF) Stock News, Apr-Nov 2025

JMPHF OTC

Welcome to our dedicated page for Leveljump Health news (Ticker: JMPHF), a resource for investors and traders seeking the latest updates and insights on Leveljump Health stock.

LevelJump Healthcare Corp. provides teleradiology and diagnostic imaging services through telehealth solutions for client hospitals and imaging centers and in-person radiology services through its Diagnostic Centres. The company’s updates commonly cover operations serving urgent and emergency care settings, financial reporting matters, and public-company capital actions.

Recurring news themes for JMPHF include non-brokered private placements, common-share issuances, stock option grants under its equity incentive plan, shareholder meeting activity, board composition, cooperation agreements, and other governance matters tied to its status as a publicly traded healthcare services company.

Rhea-AI Summary

LevelJump Healthcare (JMPHF) announced its board has scheduled an annual and special shareholder meeting for May 26, 2026 in response to a shareholder requisition by Frank Teti and Franmar Properties requesting removal of all directors and appointment of five new directors.

The Board said it combined the annual and requisitioned special meeting because audited financial statements will be available by that date and to avoid the cost of holding two meetings in close succession, noting a prior shareholder meeting was held in September 2025. A management circular and voting instructions will be mailed to shareholders of record in advance; shareholders are not required to act now.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1354.55%
Tags
none
-
Rhea-AI Summary

LevelJump (OTC: JMPHF) reported Q3 2025 results for the three and nine months ended September 30, 2025. Q3 revenue was $4.84M, up 8.7% year‑over‑year, and nine‑month revenue was $14.1M, up 9.1% year‑over‑year. The company reported a Q3 net loss of $(26,378) and nine‑month net income of $5,754. Consolidated Q3 EBITDA was $600,677 and nine‑month EBITDA was $1.90M. The 100% owned subsidiary Canadian Teleradiology Services generated Q3 EBITDA $836,000 and nine‑month EBITDA $3.04M. A previously announced acquisition of two Calgary clinics was terminated after landlord approval was not obtained. Management cited organic clinic growth and service expansion plans in Alberta.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1354.55%
Tags
none
-
Rhea-AI Summary

LevelJump Healthcare Corp (JMPHF) received a notice of requisition on November 3, 2025 requesting a shareholders' meeting under section 105(1) of the Business Corporations Act (Ontario).

The Requisition, submitted by Frank Teti and Franmar Properties Ltd., seeks to: (i) remove all five incumbent directors and (ii) elect five named nominees — Claude Ayache, Rob Saltsman, Jeff Stevens, Sheldon Levy, and Tasheel Jeerh. The company said it is reviewing the Requisition and will respond within the time required by the Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1354.55%
Tags
none
Rhea-AI Summary

LevelJump Healthcare (OTC: JMPHF) announced trading on the TSX Venture Exchange is expected to resume on or about October 9, 2025. The company says 12 months of disclosure including an annual information form are available on SEDAR+ and its website.

Key corporate updates include director re-elections at the September 4, 2025 AGM, Exchange acceptance notices for existing management consulting agreements, and insider loans totaling an aggregate requested maximum of $1,900,000 (with $65,288 advanced against the additional $309,457 request). The company filed interim June 30, 2025 financials showing a $2,637,203 working capital deficiency and canceled a planned purchase of its leased headquarters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1354.55%
Tags
none
-
Rhea-AI Summary

LevelJump Healthcare (TSXV: JUMP) has released its Q2 2025 financial results, showing consistent growth in revenues and operational performance. The company reported Q2 2025 revenues of $4.7 million, up 6.2% from the previous year, and six-month revenues of $9.3 million, representing a 9.4% increase year-over-year.

The company's subsidiary, Canadian Teleradiology Services, achieved an EBITDA of $1.01 million in Q2 and $2.23 million for the six-month period. Additionally, LevelJump is proceeding with its previously announced acquisition of two diagnostic imaging clinics in Calgary, with the transaction expected to close by October 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-69.95%
Tags
none
-
Rhea-AI Summary

LevelJump Healthcare (TSXV: JUMP) has announced that the Ontario Securities Commission (OSC) has revoked its Failure-to-File Cease Trade Order (FFCTO) that was issued on May 7, 2025. The company has now met all continuous disclosure obligations under securities legislation and is actively seeking reinstatement of trading on the TSX Venture Exchange.

The company will issue a news release before trading resumes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
LevelJump Healthcare Corp. reported strong Q1 2025 financial results with revenues of $4.58 million, representing a 12.8% increase from Q1 2024's $4.06 million. The company achieved a net profit of $200,566 and EBITDA of $898,017. Its subsidiary, Canadian Teleradiology Services, contributed $1.03 million in EBITDA. The company expects the revocation of a cease trade order after becoming current with disclosure obligations. Additionally, LevelJump has agreed to acquire two diagnostic imaging clinics in Calgary, with the deal expected to close in July 2025. The company anticipates trading reinstatement on the TSX Venture Exchange once the cease trade order is lifted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
LevelJump Healthcare Corp. reported strong financial results for 2024, with revenues reaching $17.7 million, representing a 41% increase from $12.6 million in 2023. The company's Q4 2024 revenue was $4.8 million with a net profit of $1.95 million, while the full-year net profit stood at $1.2 million. Canadian Teleradiology Services, their wholly-owned subsidiary, achieved EBITDA of $3.35 million. The company reported full-year EBITDA of $1.54 million, with Q4 EBITDA at $395,936. LevelJump is currently interpreting imaging scans for approximately 200,000 patients annually. Post year-end, the company announced plans to acquire two diagnostic imaging outpatient clinics in Calgary, Alberta, with the transaction expected to close by July 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
LevelJump Healthcare's subsidiary CTS has signed a definitive agreement to acquire two diagnostic imaging clinics in Calgary, Alberta for $1.92 million in cash. The IHFs provide x-ray, ultrasound, and mammography services, generating combined revenue of $2.2 million and EBITDA of $500,000. The acquisition, expected to close in July 2025, is subject to regulatory approval, due diligence, and securing institutional financing. Additionally, the company announced a delay in filing its 2024 year-end reporting documents, now expected within 7-10 days, after which it will seek to lift the current cease trade order and reinstate trading on TSX Venture Exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

LevelJump Healthcare has announced a delay in filing its annual audited financial statements for the fiscal year ending December 31, 2024. The company expects a cease trade order from the Ontario Securities Commission due to missing the April 30, 2025 deadline.

The delay stems from the company's significant growth, with gross revenues increasing over 30% between September 2023 and September 2024, primarily due to Alberta acquisitions. To address these challenges, LevelJump has:

  • Implemented new accounting software and controls
  • Engaged Ernst & Young as external consultants
  • Made improvements following OSC's disclosure review

LevelJump expects to file the required documents within 30 days after the deadline and plans to apply for reinstating its TSX Venture Exchange listing afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Leveljump Health (JMPHF)?

The current stock price of Leveljump Health (JMPHF) is $0.04275 as of March 30, 2026.

What is the market cap of Leveljump Health (JMPHF)?

The market cap of Leveljump Health (JMPHF) is approximately 4.7M.